Fine-Tuning Next-Generation Bispecific ADCs for Improved Efficacy & Safety

• Leveraging site-specific conjugation and linker-payload technologies to advance a pipeline of ADCs
• Exploring preclinical development of bispecific ADCs aspiring to minimise on-target toxicity and overcome tumour heterogeneity
• Optimising the bispecific format for optimal effect on tumour cells with varying antigen expression and discussing translation of functional in vitro data into in vivo efficacy

Speakers:

Sarka Stehlikova

Director, Biologics Core Technologies

SOTIO Biotech